Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
NCT ID: NCT03290768
Last Updated: 2021-05-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
358 participants
INTERVENTIONAL
2017-09-13
2018-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
NCT03252964
Continuous Glucose Monitoring in Patients With Type 2 Diabetes
NCT00529815
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
NCT03620357
Data Acquisition to Model Glycemic Response
NCT03612999
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes
NCT01341067
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetes Management Educational Program
Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
Continuous Glucose Monitor (CGM)
Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
Activity Tracker
Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
Coaching
Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Continuous Glucose Monitor (CGM)
Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
Activity Tracker
Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
Coaching
Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be able to read and understand English
* Have access to a telephone
* Have a Medicare Advantage health plan through Senior Dimensions
Exclusion Criteria
* Blind
* Deaf
* Receiving chemotherapy or radiation to treat cancer (now or in past 6 months)
* Misusing any drugs (including alcohol, painkillers, hallucinogens, or others)
* Critically ill
* Diagnosed with or experiencing:
* Kidney disease stages 4 and 5
* End stage renal disease
* Severe liver disease
* Dementia
* Schizophrenia
* Bipolar disorder
* Autism
* An intellectual or learning disability
* Arrhythmias other than atrial fibrillation
* Congestive heart failure
* Has had a:
* Myocardial infarction within the last 6 months
* Stroke within the last 6 months
* Stroke that resulted in significant disability (e.g., unable to write clearly or walk)
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Savvysherpa, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southwest Medical Associates
Las Vegas, Nevada, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00022589
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.